EFFECT - Climb Bio, Inc. (0001768446) (Filer)

S-3 - Climb Bio, Inc. (0001768446) (Filer)

8-K - Climb Bio, Inc. (0001768446) (Filer)

10-Q - Climb Bio, Inc. (0001768446) (Filer)

8-K - Climb Bio, Inc. (0001768446) (Filer)

Leerink Partners initiated coverage of Climb Bio with a rating of Outperform and set a new price target of $10.00

4 - Climb Bio, Inc. (0001768446) (Issuer)

4 - Climb Bio, Inc. (0001768446) (Issuer)

3 - Climb Bio, Inc. (0001768446) (Issuer)

WELLESLEY, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM) today announced the appointment of Douglas E. Williams, Ph.D., as Climb Bio's Chair of its Board of Directors. Dr. Williams will assume the role of Chair of the Board, succeeding Andrew Levin, who will remain on the Board as a director, while Liam Ratcliffe will step down from his position as a director. Dr. Williams has over 30 years of executive leadership experience in the biotechnology sector. Throughout his career, Dr. Williams has held leadership roles in research and development, contributing significantly to the creation of drugs such as Leukine®, Enbrel®, Adcetris®, Tecfidera®, Alprolix®, Eloctate® a

WELLESLEY HILLS, Mass., Dec. 19, 2024 (GLOBE NEWSWIRE) -- December 19, 2024 – Climb Bio, Inc. (NASDAQ:CLYM) today announced that the company will be added to the NASDAQ Biotech Index (NASDAQ:NBI) as part of the annual reconstitution of the 2024 Nasdaq indexes. Climb Bio's inclusion in the Nasdaq Biotechnology Index will be effective prior to market open on Monday, December 23, 2024. The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (Nasdaq®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). The NASDAQ Biotechnology Index is calculated under a mo

Appointed Douglas Williams, Ph.D. as Chair of the Board of Directors FDA Clearance of Investigational New Drug Application (IND) for systemic lupus erythematosus (SLE) Expanded Management Team with the Appointment of Gary Hao, Ph.D. as Vice President of Chemistry, Manufacturing and Controls Highlights Timing of Key Upcoming Milestones Cash Runway Remains through 2027 Expected to Enable Delivery of Key Value Inflection Points WELLESLEY HILLS, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today reported financial results for the quarter

WELLESLEY, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM) today announced the appointment of Douglas E. Williams, Ph.D., as Climb Bio's Chair of its Board of Directors. Dr. Williams will assume the role of Chair of the Board, succeeding Andrew Levin, who will remain on the Board as a director, while Liam Ratcliffe will step down from his position as a director. Dr. Williams has over 30 years of executive leadership experience in the biotechnology sector. Throughout his career, Dr. Williams has held leadership roles in research and development, contributing significantly to the creation of drugs such as Leukine®, Enbrel®, Adcetris®, Tecfidera®, Alprolix®, Eloctate® a

WELLESLEY, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), announced that members of its executive team are scheduled to participate in the upcoming investor conferences detailed below. Guggenheim Securities Healthcare Innovation ConferenceFormat: Fireside chat and one-on-one investor meetingsDate: November 11-12, 2024 Stifel 2024 Healthcare ConferenceFormat: Fireside chat and one-on-one investor meetingsDate: November 18-19, 2024 36th Annual Piper Sandler Healthcare ConferenceFormat: Fireside chat and one-on-one investor meetingsDate: December 3-5, 2024 7th Annual Evercore ISI HealthCONx ConferenceFormat: Fireside chat and one-on-one investor me

Completes Transition to Immune-Mediated Disease Focused Company Highlights Additional Data from Phase 1b Primary Membranous Nephropathy (pMN) Study with plans to Advance to Late Phase Development in 2025 Outlines Plans for Clinical Trials in Systemic Lupus Erythematosus (SLE) and Immune Thrombocytopenia (ITP) with First Patients Dosed Targeted for 1H25 Cash runway through 2027 Expected to Enable Delivery of Key Value Inflection Points Virtual Investor Event to be Held at 12:00 p.m. ET Today WELLESLEY HILLS, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), will be hosting a virtual investor event, today, October 15, 2024, from 12:00 p.m. to 2:

WELLESLEY, Mass., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), announced that it will present data at the American Society of Nephrology Kidney Week 2024, which will take place in San Diego, CA from October 23-27, 2024. Poster Presentation A Phase 1b Single Arm Open-Label Study of Budoprutug, an Anti-CD19 Monoclonal Antibody with Enhanced ADCC, in Primary Membranous NephropathyPresenter: Frank Cortazar, M.D., Director, New York Nephrology Vasculitis and Glomerular Center;Chief, Division of Nephrology, St. Peter's Hospital; Chief, Clinical Research, St. Peter's Health Partners;Clinical Scientist, Massachusetts General HospitalSession Title: Membranous Nephropathy, FSG

WELLESLEY, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), announced today it will present and host investor meetings at William Blair's Transforming Autoimmune Diseases by Targeting CD19 event being held in New York, NY on Wednesday, October 16, 2024. About Climb Bio, Inc. Climb Bio, Inc., is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. For more information, please visit climbbio.com. InvestorsChris Brinzey ICR

SC 13G/A - Climb Bio, Inc. (0001768446) (Subject)